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Background: Anastomotic leakage is a major complication in colorectal surgery and with an incidence of 11% the
most common cause of morbidity and mortality. In order to reduce the incidence of anastomotic leakage the
C-seal is developed. This intraluminal biodegradable drain is stapled to the anastomosis with a circular stapler and
prevents extravasation of intracolonic content in case of an anastomotic dehiscence.
The aim of this study is to evaluate the efficacy of the C-seal in reducing anastomotic leakage in stapled colorectal
anastomoses, as assessed by anastomotic leakage leading to invasive treatment within 30 days postoperative.
Methods: The C-seal trial is a prospective multi-center randomized controlled trial with primary endpoint,
anastomotic leakage leading to re-intervention within 30 days after operation. In this trial 616 patients will be
randomized to the C-seal or control group (1:1), stratified by center, anastomotic height (proximal or distal of
peritoneal reflection) and the intention to create a temporary deviating ostomy. Interim analyses are planned after
50% and 75% of patient inclusion. Eligible patients are at least 18 years of age, have any colorectal disease requiring
a colorectal anastomosis to be made with a circular stapler in an elective setting, with an ASA-classification < 4.
Oral mechanical bowel preparation is mandatory and patients with signs of peritonitis are excluded. The C-seal
student team will perform the randomization procedure, supports the operating surgeon during the C-seal
application and achieves the monitoring of the trial. Patients are followed for one year after randomization en will
be analyzed on an intention to treat basis.
Discussion: This Randomized Clinical trial is designed to evaluate the effectiveness of the C-seal in preventing
clinical anastomotic leakage.
Trial registration: NTR3080Background
Anastomotic Leakage (AL) is the most important com-
plication after colorectal surgery and leads to high rates
of morbidity, prolonged hospitalization, commonly
requires re-interventions, and can result in death [1].
The incidence of AL varies in the literature between 4
and 20% [2-6]. This considerable variation may be due to* Correspondence: i.s.bakker@umcg.nl
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reproduction in any medium, provided the orthe fact that different definitions are used. The Inter-
national Study Group of Rectal Cancer (ISGRC) proposed
a standardized definition for AL according to clinical
grading [7]. AL is defined as a defect of the intestinal wall
at the anastomotic site leading to a communication be-
tween the intra and extraluminal compartments. An ab-
scess in the proximity of the anastomosis is considered to
be AL. The severity of AL is classified in three grades.
Grade A AL corresponds to the definition ‘radiologic leak-
age’ for which no intervention is required. Grade B AL
requires an active therapeutic intervention but could beLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 C-seal attached to the anvil of the circular stapler.
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relaparotomy [7].
Recent data from the Dutch Surgical Colorectal Audit
(DSCA) showed an AL rate of 11% leading to re-
intervention in the Netherlands [8].
In order to reduce the incidence of AL the C-seal is
developed. The C-seal is an intraluminal biodegradable
drain which is stapled to the anastomosis with a circular
stapler [9]. The C-seal covers the intraluminal side of
the anastomosis and prevents extravasation of intracolo-
nic content to the peritoneal cavity in case of anasto-
motic dehiscence.
In previous studies performed in the University Medical
Center Groningen (UMCG) and in some other clinics a
total amount of 52 patients were treated with the C-seal.
The pilot study of fifteen patients, who underwent a colo-
rectal resection with a C-seal, showed that the application
of the C-seal was feasible and there were no clinical or
radiological signs of leakage [10]. Also the subsequent
phase II study with 37 patients confirmed the feasibility of
the C-seal by both surgeons and by patients. There were
no serious adverse events reported related to the C-seal
[11]. Furthermore this study showed promising results in
the reduction of clinical AL, which led to the initiation of
a randomized controlled trial, the C-seal trial. This trial
aims to compare the outcome for stapled colorectal anas-
tomoses made with and without a C-seal.
The main objective of the C-seal trial is to evaluate the
efficacy of the C-seal in reducing AL in stapled colorec-
tal anastomoses, as assessed by AL leading to invasive
intervention within 30 days postoperative.
Methods
Design
The C-seal trial is a prospective multi-center rando-
mized controlled trial, initiated by the department of
surgery, division of abdominal surgery of the UMCG,
the Netherlands. The study will be performed in ap-
proximately 35 clinics.
In this trial 616 patients will be randomized equally
between the C-seal group and the control group. The
study protocol is approved by the central medical ethics
committee of the UMCG. In all participating centers a
local feasibility agreement is arranged. Patients will be
followed until one year after randomization.
Participants
Eligible patients are diagnosed with any colorectal dis-
ease requiring a colorectal anastomosis in an elective set-
ting, have a minimum age of 18 years and an ASA
classification < 4. Preoperative mechanical bowel prepar-
ation is mandatory, but can be omitted if the patient has
a previously created deviating ostomy that will remain in
situ. Patients with clinical signs of peritonitis and patientswho underwent major surgery 30 days prior to the oper-
ation or have major surgery planned within 30 days after
the procedure, are excluded.
All eligible patients visiting the surgical outpatient de-
partment in participating centers will be informed about
the trial. Informed Consent must be obtained before
inclusion.
The participating study sites should comply with the
recent guidelines of the Dutch Society of Surgery to per-
form colorectal surgery (Normering Chirurgische behan-
deling. NVvH January 2011). The operating surgeons are
adequately trained in the application of the C-seal.
Intervention
Fifty percent of the study population will be randomized
to the C-seal group and 50% to the control group. The
C-seal is stapled to the anastomosis with a circular stap-
ler. Before creating the anastomosis the C-seal is
attached to the anvil of the circular stapler (Figure 1) and
together they are inserted in the proximal bowel loop.
After firing the circular stapler the C-seal is stapled to
the mucosal side of the afferent loop (Figure 2). When
the stapler is removed from the anus, the C-seal is
brought through the anus and cut from the stapler anvil.
The application of the C-seal to the anvil is trained in a
practicum session provided to the participating operating
surgeons and local research group.
Postoperatively the C-seal will be in situ for approxi-
mately two weeks. The C-seal degrades in time and
secretes through the anus together with bowel contents.
Outcome
The primary endpoint of the C-seal trial is the incidence
of AL leading to invasive treatment within 30 days after
surgery. AL is defined based on the classification accord-
ing the ISGRC classification.
Secondary endpoints are the number of dismantled
anastomoses, the number of ostomies created, the number
Figure 2 Intraluminal attachment of the C-seal after the staple
procedure.
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pital stay, the interval between primary surgery and the
diagnosis of AL, the incidence of late AL (≥ 30 days and
within 1 year) and a differentiation between grade A, B or
C AL classified according the ISGRC [7].Sample size
The sample size of 616 patients is determined with a
power analysis based on a power of 90%, a significance
level of 5%, AL percentage of 4% in the C-seal group and
10% AL in the control group.Randomization
Patients are equally distributed to either the C-seal or the
control group. In an attempt to overcome possible bias,
the randomization procedure is performed in the operating
room during surgery. The randomization procedure is per-
formed by a C-seal student with an online randomization
system. The randomization is stratified for center, high or
low anastomosis (respectively proximal or distal of the
peritoneal reflection) and the intention to create a tempor-
ary deviating ostomy.Statistical analysis
Primary and secondary endpoints will be analyzed on an
intention to treat basis. The groups will be compared by
means of a Fisher’s exact test.
After 50% and 75% of patient enrollment an interim
analysis will be performed based on Snapinn’s stopping
rule [12].Discussion
This study investigates the efficacy of the C-seal in the
prevention of clinical AL in stapled colorectal anasto-
moses. The concept of the protection of a colorectal
anastomosis by means of an intraluminal device has
already been described [13-15]. Based on the idea that
intraluminal devices in colorectal anastomoses protect
the fecal stream from anastomotic contact, there will be
no leakage if anastomotic dehiscence develops. Under
the device a perforation can still arise, but because there
is no fecal spill this probably will not lead to a fecal peri-
tonitis. Local inflammation may cause adhesions and
cover the defect and symptoms of a possible leak are
probably less severe [13,16].
It is also hypothesized that AL in colorectal anasto-
moses is frequently caused by poor vascularization
through intraoperative mechanical manipulation [17,18],
often from the distal rectal stump [19]. Since the C-seal
is attached to the proximal bowel loop, the C-seal
remains in situ if the rectal stump is poorly vascularized
and leads the fecal stream in the first postoperative
weeks outside the body without contact with the rectal
wall. After about two weeks the biodegradable drain
degrades and is excreted through the anus.
In this study the required sample size is determined
based on the current AL rate in the Netherlands. To give a
good reflection of the colorectal surgery in the Netherlands
and in order to approach this AL incidence, 35 different
hospitals, ranging from small referral hospitals to academic
centers, are participating in the trial. The participation of
this large number of clinics creates possible challenges in
protocol adherence. To standardize procedures all operat-
ing surgeons are trained by the C-seal research team from
the UMCG and during the surgery a student from the
C-seal team attends the procedure. To overcome a possible
bias regarding the participation of many clinics the
randomization is stratified for center.
In addition to the stratification for center, there is also
stratified for the intention to create a deviating ostomy
and for anastomotic height. The stratification for the
intention to create a deviating ostomy is performed to
prevent selection bias. The outcome of randomization
(C-seal or not) may influence operating surgeons in their
decision to create a deviating ostomy. Therefore, the
intention to create a deviating ostomy must be docu-
mented before the patient is randomized at the OR.
A limitation of the study may be that we have chosen
not to stratify for neoadjuvant therapy. Most patients
with rectal cancer in the Netherlands are treated with
neoadjuvant radiotherapy. From the literature it is con-
cluded that short scheme radiotherapy is not a signifi-
cant risk factor for the occurrence of AL [20,21]. Results
of studies with long scheme chemo radiation however
are inconsistent in the influence on the incidence of AL.
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rence of AL [22,23], while results from other studies did
not found this increase in the incidence of AL [24,25].
Because a large study population will be included in
this trial, the patients will be proportionally allocated to
both groups.
With the results of this randomized controlled trial we
compare the incidence of AL leading to re-intervention
in patients treated with a C-seal to patients treated with-
out a C-seal.
Secondary to this prospective trial a few side studies
will be performed. With the use of intraoperative col-
lected data of anaesthesiological parameters as oxygen-
ation, blood tension, temperature and the use of
vasoconstrictive medication eg, we attempt to identify
potential contributing factors for the occurrence of AL.
Also intraoperative data of the technical aspects of the
stapling process are noted in the CRF to evaluate the
surgical technique used to create an anastomosis in the
Netherlands and the possible relation this could have in
causing AL. Adjacent to the clinical trial translational re-
search will be conducted with blood draws and bowel
samples of the proximal and distal donuts of the
included patients, collected during the surgery. With
these patient materials we aim to correlate molecular tis-
sue characteristics as pro-inflammatory proteins, Matrix
Metallo Proteinases and C-reactive protein with clinical
outcome. In blood plasma, indicators of inflammation,
bacterial translocation and intestinal damage will be
determined and will be correlated with the molecular
profile of the patients.
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